icon bookmark-bicon bookmarkicon cameraicon checkicon chevron downicon chevron lefticon chevron righticon chevron upicon closeicon v-compressicon downloadicon editicon v-expandicon fbicon fileicon filtericon flag ruicon full chevron downicon full chevron lefticon full chevron righticon full chevron upicon gpicon insicon mailicon moveicon-musicicon mutedicon nomutedicon okicon v-pauseicon v-playicon searchicon shareicon sign inicon sign upicon stepbackicon stepforicon swipe downicon tagicon tagsicon tgicon trashicon twicon vkicon yticon wticon fm

Britain could approve fourth Covid jab in 4 weeks, says Novavax trial chief, as EU demand ‘fairer share’ of UK’s vaccines

Britain could approve fourth Covid jab in 4 weeks, says Novavax trial chief, as EU demand ‘fairer share’ of UK’s vaccines
The chief investigator for the Novavax vaccine trial in the UK has claimed their injection could be reviewed and ready for rollout within a month as GlaxoSmithKline pens contract to “fill and finish” the jab in Britain.

Speaking to the Evening Standard on Tuesday, Novavax’s vaccine trial chief Professor Paul Heath said its approval would help maintain the “momentum” of Britain's immunization programme. 

“The regulator will do a very detailed and thorough review and will decide in good time,” he said, adding “I would hope it would be in the spring, possibly end of April.”

Heath claimed that the firm has given nearly all the required data to the Medicines and Healthcare products Regulatory Agency (MHRA) for them to conclude their “rolling review” process.

The vaccine was found to have 86% efficacy against the British variant of Covid-19 and be 96% effective against the original virus strain. Sixty million doses of the jab have been ordered by the British government which will be manufactured at the Fujifilm plant in Billingham, England’s North-East.

The final stage of the vaccine’s manufacture will be carried out by GlaxoSmithKline, as announced by the prime minister on Monday, at another facility in the North East of England.

If approved by the MHRA, the jab will be the UK’s fourth vaccine ready for rollout after the shots produced by Pfizer, AstraZeneca and Moderna. 

Also on rt.com London has no plans to share Covid vaccines with Republic of Ireland, PM’s office says despite reports

On Monday, PM Boris Johnson said Britain was keen to continue developing vaccine manufacturing capacity. If approved, a further vaccine, developed by Valneva will be manufactured in Scotland. 

The UK and the EU are currently engaged in talks in order to achieve a “fairer deal” for the 27-nation bloc. Brussels believes London should start sharing some of the jabs manufactured in the UK with European nations as a reciprocal measure for doses made in the EU which were distributed to the UK.  

Also on rt.com UK signs deal for GlaxoSmithKline to produce 60 million doses of Novavax Covid-19 vaccine

On Monday, Johnson’s government dismissed rumours it was ready to provide jabs to the Republic of Ireland in an effort to prevent Covid-19 infections being imported into Northern Ireland as Belfast relaxes restrictions.

The UK has made significantly more progress than EU countries in vaccinating against Covid-19. More than 57% of British adults have been inoculated, while many EU countries are yet to hit 15%. 

Like this story? Share it with a friend!

Podcasts